Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.

Kentaro MiyakeTasuku KiyunaKei KawaguchiTakashi HiguchiHiromichi OshiroZhiying ZhangSintawat WangsiricharoenSahar RazmjooeiYunfeng LiScott D NelsonTakashi MurakamiYukihiko HiroshimaRyusei MatsuyamaMichael BouvetSant P ChawlaShree Ram SinghItaru EndoRobert M Hoffman

Published in: Cancer chemotherapy and pharmacology (2019)

Our findings suggest that REG has clinical potential for ES patients whose tumors respond to REG in a PDOX model.

Keyphrases

mouse model
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
drug delivery
risk assessment
cancer therapy